Nootropics Index - Save on smarter supplements
Nootropics>Botanical & herbal supplements>Magnolia Bark
Botanical & herbal supplements

Magnolia Bark

Magnolia officinalis bark extract

Magnolia Bark usually means Magnolia officinalis bark extract, often standardized for honokiol and magnolol. Small human stress and mood trials used Relora, a Magnolia/Phellodendron blend; their results and doses cannot establish how a standalone bark product works. Compare extract identity, marker percentage, amount per serving and the full formula before price. Sleep benefits, same-day duration and a standalone nootropic dose remain unestablished; drug interactions and long-term safety also need caution.

CalmRelaxationStress ResilienceMood SupportStandardized ExtractTraditional UseLimited Human Evidence
Updated October 2026/7 min read/11 citations
Reviewed by the NootropicsIndex editorial team.Method: prioritize cited human research and official safety or regulatory sources; compare retailer-listed prices without endorsing products.Affiliate disclosure
01

What is it?

What it is

2

Magnolia Bark refers here to Magnolia officinalis bark extracts, also known as Hou Po. Honokiol and magnolol are constituent markers. An isolated constituent, a concentrated extract and a multi-ingredient formula are different products, even when the label mentions Magnolia.

Blend evidence is not standalone bark proof5
Relora combines Magnolia officinalis and Phellodendron amurense extracts and was standardized to at least 1.5% honokiol and 0.1% berberine in the cited trials. A standalone bark extract with a different marker profile cannot inherit that formula's results or dose.
Small stress and mood trial6
A four-week Relora trial in 56 moderately stressed adults reported lower salivary cortisol exposure and better mood questionnaire scores than placebo, with no reported adverse events. The sample was small, industry-funded and specific to this blend.
Sleep outcomes did not beat placebo7
In the pilot, 40 women were included in the efficacy analysis and 26 completed the study. Temporary anxiety scores improved, but sleep quality, sleep latency, cortisol and trait-anxiety outcomes did not differ significantly from placebo. This does not establish a sleep benefit from standalone bark.
02

Names, aliases and forms

Common NameMagnolia Bark
Scientific NameMagnolia officinalis
Traditional NameHou Po
Spelling VariantHoupu magnolia
Extract NameMagnolia bark extract
03

Mechanisms of action

Honokiol and magnolol markers

2

Honokiol and magnolol have laboratory and animal pharmacology, including GABA-related activity. That provides a research rationale, not proof of a human cognitive or sleep benefit; a marker percentage alone cannot establish clinical equivalence.

04

Potential effects and evidence map

Human stress and mood findings are limited and largely indirect for standalone Magnolia bark: small trials used the proprietary Magnolia/Phellodendron blend Relora. The six-week pilot did not show a sleep-quality or sleep-latency advantage over placebo. Preclinical honokiol/magnolol activity does not establish a cognitive benefit, a human onset time or equivalence between extracts.

Effect domainMagnitudeGrade
Focus / attention2
UnknownConfidence: High

No human focus or attention benefit is established for standalone Magnolia bark.

Note Zero denotes no established clinical signal, not proof of no possible effect. The blend stress studies do not quantify a standalone cognitive benefit.

0/5
E
05

Typical dosages and timing

formulation-specific trials6500-750 mg/day

The four-week study used 500 mg/day of Relora; the six-week pilot used 250 mg three times daily. These are blend amounts, not a validated standalone Magnolia dose or a target honokiol dose. Different extract concentrations cannot be compared by bark mass alone.

06

Timing & effect horizon

Effect horizonUnknown
Unknown
Relora trial5Cumulative
4 weeks
Relora pilot7Cumulative
6 weeks
Study windows do not establish onset5

The featured values are Relora observation windows. They do not establish when a single bark dose starts working, how long it lasts, a human The time for blood levels to fall by half during the final elimination phase.Source, a recommended cycle or the effect horizon of a standalone extract. Those timing questions remain unresolved.

07

Safety, side effects and risk profile

Overall risk is unscored7
Bark products vary in marker content, while the relevant stress trials tested a blend. They cannot calibrate a numeric risk for ordinary standalone oral use. In the six-week pilot, two Relora users withdrew after adverse symptoms, including heartburn, shaking, mouth-area numbness, reported sexual or thyroid dysfunction, fatigue and headache. No serious events were recorded; causation by Magnolia alone was not established. Long-term safety and potential medicine interactions remain uncertain.
Possible additive sedative effects2
MSK flags possible additive effects with sleep or anxiety medicines, including benzodiazepines. Clinical relevance is unknown; this is a precaution rather than a measured rate of impairment from bark alone.
Sedation / impairment2
Confidence: Low

Potential additive effects with benzodiazepines and other sedating medicines are a precaution; the clinical magnitude is unknown.

Note This monograph caution is not an incidence estimate for ordinary standalone oral use.

Unscored
D
Pregnancy / lactation caution7
Confidence: Low

Pregnancy and lactation were excluded from the pilot trial; these populations have no established safety margin.

Note An evidence gap is not a quantified reproductive-harm rating.

Unscored
E
Evidence uncertainty7
Confidence: High

Small blend trials cannot calibrate the overall risk of bark products with different extract compositions.

Note Unknown does not mean safe: trial adverse events and possible drug interactions remain described separately.

Unscored
C
GI discomfort7
Confidence: Low

One Relora participant who withdrew reported heartburn along with other symptoms; attribution to Magnolia alone is not possible.

Note Blend-specific adverse-event report; no standalone incidence or severity score is assigned.

Unscored
C
Headache / dizziness7
Confidence: Low

Fatigue and headache were reported by a Relora participant who withdrew from the six-week pilot.

Note Preserves the human tolerability signal without inferring a standalone bark risk magnitude or a dizziness signal.

Unscored
C
insufficient safety data7

The Relora pilot excluded pregnant and lactating participants. Its results provide no established safety margin for these populations or for children.

contact allergy reports11

Contact dermatitis has been reported after cosmetic exposure to Magnolia officinalis bark extract. This route-specific observation does not quantify oral allergy risk.

08

Interactions and cautions

possible additive effects2

Preclinical findings underlie cautions about antiplatelet and glucose-lowering medicines. The magnitude of any interaction in people is unknown. A supplement label is not evidence that combining these products is safe.

CYP / P-gp / UGT9

Honokiol inhibited several CYP and UGT enzymes in human liver microsomes; a separate cell study found P-gp changes. These experiments do not establish a clinical drug interaction or its dose threshold, but warrant caution with medicines sensitive to exposure changes.

09

Practical buying and quality notes

  • Check botanical identity, bark part, extraction method, serving mass and honokiol/magnolol percentage. Serving mass multiplied by a disclosed percentage estimates marker mass: 200 mg at 10% combined markers contains 20 mg combined markers. That arithmetic does not establish a dose recommendation or equivalence to Relora.6
  • Compare price per serving only after checking extract concentration and other ingredients. A Relora blend, standalone bark and isolated honokiol are not interchangeable units. Check a batch-specific identity and contaminant certificate; a low price alone cannot show equivalent composition.7
10

FAQ

Is Magnolia Bark a nootropic?

2

There is no established human evidence for focus or memory enhancement from standalone Magnolia bark. Small blend-based stress findings and preclinical constituent studies do not establish those outcomes.

Is there an established standalone bark dose?

6

No comparable human nootropic dose is established across extracts. The doses above belong to the studied Relora formula. Check whether a product is bark, a standardized extract, an isolated marker or a blend before interpreting milligrams.

How long does it last, and should it be cycled?

7

A reliable human single-dose duration, tolerance pattern and cycling schedule are not established for standalone bark. The trial windows above are observation periods, not suggested cycles.

Who should be most cautious?

2

Medication use, pregnancy, lactation and products with additional sedating ingredients need particular caution. The available evidence does not establish a safe combination or a reproductive safety margin.

11

References

  1. NCBI Taxonomy. Magnolia officinalis. Taxonomy ID 85864.
  2. Memorial Sloan Kettering Cancer Center. Magnolia officinalis. About Herbs.
  3. PubChem. Compound Summary for CID 72303, Honokiol.
  4. PubChem. Compound Summary for CID 72300, Magnolol.
  5. Talbott SM, Talbott JA, Pugh M. Effect of Magnolia officinalis and Phellodendron amurense (Relora) on cortisol and psychological mood state in moderately stressed subjects. J Int Soc Sports Nutr. 2013;10(1):37.
  6. Talbott SM, Talbott JA, Pugh M. Full text: Relora study methods and dose details.
  7. Kalman DS, Feldman S, Feldman R, Schwartz HI, Krieger DR, Garrison R. Effect of a proprietary Magnolia and Phellodendron extract on stress levels in healthy women: a pilot, double-blind, placebo-controlled clinical trial. Nutr J. 2008;7:11.
  8. Garrison R, Chambliss WG. Effect of a proprietary Magnolia and Phellodendron extract on weight management: a pilot, double-blind, placebo-controlled clinical trial. Altern Ther Health Med. 2006;12(1):50-54.
  9. Jeong HU, Kong TY, Kwon SS, Hong SW, Yeon SH, Choi JH, Lee JY, Cho YY, Lee HS. Effect of honokiol on cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in human liver microsomes. Molecules. 2013;18(9):10681-10693.
  10. Han HK, Van Anh LT. Modulation of P-glycoprotein expression by honokiol, magnolol and 4-O-methylhonokiol, the bioactive components of Magnolia officinalis. Anticancer Res. 2012;32(10):4445-4452.
  11. Ghys K, De Palma A, Vandevenne A, Werbrouck J, Goossens A. Magnolia officinalis bark extract, a recently identified contact allergen in anti-ageing cosmetics. Contact Dermatitis. 2015;73(2):130-132.
Note

This page is informational and summarizes available evidence. It is not medical advice, a recommendation, or a substitute for guidance from a qualified clinician.